Xilio Therapeutics (XLO) reported third-quarter 2026 collaboration and license revenue of $10.0 million and a net loss of $5.9 million, or $0.30 per basic and diluted share. Cash and cash equivalents totaled $122.2 million at September 30, 2026.
The company dosed the first patient in its Phase 1/2 trial of XTX501 for metastatic non-small cell lung cancer and select advanced solid tumors. Xilio plans to report initial Phase 1 data for metastatic NSCLC in the fourth quarter of 2027.
- Third-quarter collaboration and license revenue was $10.0 million, compared with $19.1 million a year earlier.
- R&D expense was $14.8 million, while G&A expense was $6.9 million.
- Xilio plans fourth-quarter 2027 IND submissions for XTX602 and XTX701.
- The company expects existing cash and cash equivalents to fund operations into the first quarter of 2028.
$XLO Hedge Fund Activity
We have seen 13 institutional investors add shares of $XLO stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIMED ADVISORS LLC added 592,300 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,674,234
- CALIGAN PARTNERS LP removed 112,128 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,074,186
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 111,541 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,068,562
- EMPERY ASSET MANAGEMENT, LP removed 84,503 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $809,538
- FMR LLC removed 36,558 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $350,225
- BRIDGEWAY CAPITAL MANAGEMENT, LLC added 17,544 shares (+inf%) to their portfolio in Q2 2026, for an estimated $168,071
- RENAISSANCE TECHNOLOGIES LLC added 14,587 shares (+29.4%) to their portfolio in Q2 2026, for an estimated $139,743
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.